CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($2.40), $1.00 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $5.81 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.